Torres, Eulalia BaselgaWittel, Jose Bernabeuvan Esso Arbolave, Diego L.Febrer Bosch, Maria IsabelSanz, Angel CarrascoLaguna, Raul de LucasLosada, Jesus del PozoMartin, Angela HernandezMontanes, Lorenzo JimenezLopez Gutierrez, Juan CarlosMartin-Santiago, AnaBellon, Pedro RedondoCaceres, Juan Ruiz-CanelaFernandez, Antonio TorreloCasano, Angel VeraVicente Villa, Maria Asuncion2023-02-122023-02-122016-11-011695-4033http://hdl.handle.net/10668/18678Introduction: Infantile haemangiomas are benign tumours produced by the proliferation of endothelial cells of blood vessels, with a high incidence in children under the age of one year (4-10%). It is estimated that 12% of them require treatment. This treatment must be administered according to clinical practice guidelines, expert experience, patient characteristics and parent preferences.Methods: The consensus process was performed by using scientific evidence on the diagnosis and treatment of infantile haemangiomas, culled from a systematic review of the literature, together with specialist expert opinions. The recommendations issued were validated by the specialists, who also provided their level of agreement.Results: This document contains recommendations on the classification, associations, complications, diagnosis, treatment, and follow-up of patients with infantile haemangioma. It also includes action algorithms, and addresses multidisciplinary management and referral criteria between the different specialities involved in the clinical management of this type of patient.Conclusions: The recommendations and the diagnostic and therapeutic algorithms of infantile haemangiomas contained in this document are a useful tool for the proper management of these patients. (C) 2015 Asociacion Espanola de Pediatria. Published by Elsevier Espana, S.L.U. All rights reserved.esAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Haemangioma/diagnosisHaemangioma/drug therapyHaemangioma/complicationsHaemangioma/classificationPropranololInfantAlgorithmsClinical characteristicsPhace syndromeRisk-factorsPropranololManagementComplicationsInfancyTimololCohortresearch articleopen access10.1016/j.anpedi.2015.10.0041696-4608https://doi.org/10.1016/j.anpedi.2015.10.004388782400006